The Economic Impact of Atopic Dermatitis
Author:
- 10 May 2024
- book chapter
- Published by Springer Nature
- Vol. 1447, 91-104
Abstract
Atopic dermatitis (AD) is a chronic inflammatory disorder that affects over 30 million people in the United States. Given the large and growing prevalence of AD, the associated economic burden is significant. It has been estimated that AD costs over $5 billion dollars annually. These costs include both direct and indirect costs. Direct costs include prescription medicines, visits to health-care providers, hospitalizations, and transportation. Indirect costs include missed days or lost productivity at work or school, career modification, and reduced quality of life. Understanding and measuring these costs can be accomplished through rigorous economic evaluation, which is the organized process of considering inputs and outcomes of various activities. Economic evaluation has been used to contextualize the burden of AD in society. It has also been used to inform patients, providers, and other stakeholders on how to deliver the most evidence-based, efficient way possible. Understanding the economic impact of atopic dermatitis is an important aspect of delivering high-quality care.Keywords
This publication has 58 references indexed in Scilit:
- The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical useBritish Journal of Dermatology, 2010
- The cost of atopic dermatitis in the Netherlands: an international comparisonBritish Journal of Dermatology, 2002
- Cost of atopic dermatitis and eczema in the United StatesJournal of the American Academy of Dermatology, 2002
- Breast-feeding and the onset of atopic dermatitis in childhood: A systematic review and meta-analysis of prospective studiesJournal of the American Academy of Dermatology, 2001
- What is the cost of atopic dermatitis in preschool children?British Journal of Dermatology, 2001
- Theory versuspractice: a review of ?willingness-to-pay? in health and health careHealth Economics, 2001
- The prevalence of atopic dermatitis in Oregon schoolchildrenJournal of the American Academy of Dermatology, 2000
- Cost-effectiveness and Cost-Benefit Analysis of Using Methotrexate vs Goeckerman Therapy for PsoriasisArchives of Dermatology, 1998
- Atopic eczema: its impact on the family and financial costArchives of Disease in Childhood, 1997
- Atopic dermatitis in children: Who cares? Who pays?Journal of the American Academy of Dermatology, 1993